1. Home
  2. TBPH vs BLW Comparison

TBPH vs BLW Comparison

Compare TBPH & BLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • BLW
  • Stock Information
  • Founded
  • TBPH 2013
  • BLW 2003
  • Country
  • TBPH United States
  • BLW United States
  • Employees
  • TBPH N/A
  • BLW N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • BLW Other Consumer Services
  • Sector
  • TBPH Health Care
  • BLW Consumer Discretionary
  • Exchange
  • TBPH Nasdaq
  • BLW Nasdaq
  • Market Cap
  • TBPH 464.5M
  • BLW 531.8M
  • IPO Year
  • TBPH N/A
  • BLW N/A
  • Fundamental
  • Price
  • TBPH $10.67
  • BLW $14.04
  • Analyst Decision
  • TBPH Buy
  • BLW
  • Analyst Count
  • TBPH 4
  • BLW 0
  • Target Price
  • TBPH $14.50
  • BLW N/A
  • AVG Volume (30 Days)
  • TBPH 305.1K
  • BLW 85.9K
  • Earning Date
  • TBPH 08-04-2025
  • BLW 01-01-0001
  • Dividend Yield
  • TBPH N/A
  • BLW 8.83%
  • EPS Growth
  • TBPH N/A
  • BLW N/A
  • EPS
  • TBPH N/A
  • BLW 1.81
  • Revenue
  • TBPH $65,266,000.00
  • BLW N/A
  • Revenue This Year
  • TBPH $43.18
  • BLW N/A
  • Revenue Next Year
  • TBPH N/A
  • BLW N/A
  • P/E Ratio
  • TBPH N/A
  • BLW $7.73
  • Revenue Growth
  • TBPH 6.11
  • BLW N/A
  • 52 Week Low
  • TBPH $7.44
  • BLW $12.35
  • 52 Week High
  • TBPH $11.82
  • BLW $14.26
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 57.88
  • BLW 54.90
  • Support Level
  • TBPH $10.44
  • BLW $13.97
  • Resistance Level
  • TBPH $11.00
  • BLW $14.15
  • Average True Range (ATR)
  • TBPH 0.30
  • BLW 0.08
  • MACD
  • TBPH -0.05
  • BLW -0.01
  • Stochastic Oscillator
  • TBPH 23.15
  • BLW 59.26

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About BLW Blackrock Limited Duration Income Trust

Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.

Share on Social Networks: